Schiro A, Wilkinson F L, Weston R, Smyth J V, Serracino-Inglott F, Alexander M Y
Regional Vascular and Endovascular Unit, Manchester Royal Infirmary, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Oxford Road, Manchester M13 9WL, UK; Cardiovascular Research Institute, Manchester Academic Health Science Centre, University of Manchester, Core Technology Facility, 46 Grafton Street, Manchester M13 9MT, UK.
Translational Science, Healthcare Science Research Institute, Faculty of Science and Engineering, Manchester Metropolitan University, John Dalton Building, Chester Street, Manchester M1 5GD, UK.
Atherosclerosis. 2014 Jun;234(2):295-302. doi: 10.1016/j.atherosclerosis.2014.03.019. Epub 2014 Mar 27.
Endothelial microparticles (EMPs) are complex submicron membrane-shed vesicles released into the circulation following endothelium cell activation or apoptosis. They are classified as either physiological or pathological, with anticoagulant or pro-inflammatory effects respectively. Endothelial dysfunction caused by inflammation is a key initiating event in atherosclerotic plaque formation. Athero-emboli, resulting from ruptured carotid plaques are a major cause of stroke. Current clinical techniques for arterial assessment, angiography and carotid ultrasound, give accurate information about stenosis but limited evidence on plaque composition, inflammation or vulnerability; as a result, patients with asymptomatic, or fragile carotid lesions, may not be identified and treated effectively. There is a need to discover novel biomarkers and develop more efficient diagnostic approaches in order to stratify patients at most risk of stroke, who would benefit from interventional surgery. Increasing evidence suggests that EMPs play an important role in the pathogenesis of cardiovascular disease, acting as a marker of damage, either exacerbating disease progression or triggering a repair response. In this regard, it has been suggested that EMPs have the potential to act as biomarkers of disease status. In this review, we will present the evidence to support this hypothesis and propose a novel concept for the development of a diagnostic device that could be implemented in the clinic.
内皮微粒(EMPs)是在内皮细胞激活或凋亡后释放到循环系统中的复杂亚微米膜脱落囊泡。它们被分为生理性或病理性,分别具有抗凝或促炎作用。炎症引起的内皮功能障碍是动脉粥样硬化斑块形成的关键起始事件。颈动脉斑块破裂导致的动脉粥样硬化栓子是中风的主要原因。目前用于动脉评估的临床技术,血管造影和颈动脉超声,能提供有关狭窄的准确信息,但关于斑块组成、炎症或易损性的证据有限;因此,无症状或脆弱颈动脉病变的患者可能无法得到有效识别和治疗。有必要发现新的生物标志物并开发更有效的诊断方法,以便对最易患中风的患者进行分层,这些患者将从介入手术中受益。越来越多的证据表明,内皮微粒在心血管疾病的发病机制中起重要作用,作为损伤的标志物,要么加剧疾病进展,要么触发修复反应。在这方面,有人提出内皮微粒有可能作为疾病状态的生物标志物。在本综述中,我们将提供支持这一假设的证据,并提出一个开发可在临床应用的诊断设备的新概念。